2016 American Transplant Congress
The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.
Efficacy of CNI- and corticosteroid-free immunosuppressive regimens has not been demonstrated in large, multicenter trials. BEST (Belatacept-based Early Steroid Withdrawal Trial) (NCT 01729494) compares 2…2016 American Transplant Congress
Serum Levels of Soluble Myeloid Antigens After Kidney Allograft Transplantation.
Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
Mononuclear phagocytes and neutrophils play a key role in early responses against the transplanted kidney allograft. It is expected that during the reperfusion of kidney…2016 American Transplant Congress
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.
Purpose: B cell subsets could be used as biomarkers to modulate therapy regimens in kidney transplant patients. B cell subsets occur with varying proportions within…2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.
CNI delay early after heart transplantation is a recommended therapeutic option according to ISHLT guidelines. However, there exist only few published data on feasibility of…2016 American Transplant Congress
Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.
Introduction: 3C study concluded that in comparison to basiliximab, alemtuzumab induction reduces the risk of biopsy proven acute rejection (BPAR) in renal transplant recipients. In…2016 American Transplant Congress
Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin.
Induction therapy with depleting antibodies reduces rejection rate and potentially improves efficacy of steroid free regimens after renal transplantation.This prospective, single-centre, cohort study evaluated cumulative…2016 American Transplant Congress
Basiliximab Induction for Safe Delay of Calcineurin Inhibitors in High MELD Liver Transplant Recipients.
Background: Available literature supports basiliximab induction for safe delay of CNI initiation and renal recovery; however there is a paucity of evidence for use in…2016 American Transplant Congress
Antithymocyte (ATG) Dose Density in Renal Transplant Recipients (RTR) with Early Graft Dysfunction (EGD).
Houston Methodist Hospital, Houston, TX.
The cumulative amount of ATG for induction may be given as consecutive (cDD) or intermittent day dosages (iDD). iDD allows for leukocyte or platelet recovery…2016 American Transplant Congress
Associations of Risk Factors and Kidney Retransplant Outcomes Vary Between Three Common Induction Agents: Results from the Analysis of Over Ten-Thousand Cases in Ten Years.
Medicine, University of Florida, Gainesville, FL.
BACKGROUND: There is no published study comparing the significance of risk factors for graft outcomes associated with common induction regimens combined with tacrolimus and mycophenolate…2016 American Transplant Congress
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.
Introduction:HLA specific antibodies detection (HSA) and that of Donor Specific Antibodies (DSA) were revolutionized by the introduction of solid phase assays (Luminex®), therefore making these…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 31
- Next Page »